The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo DrugZacks Investment Research • 12/29/25
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.The Motley Fool • 12/29/25
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?Zacks Investment Research • 12/24/25
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss PillThe Motley Fool • 12/23/25
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In FocusBenzinga • 12/23/25
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly's Looming Pill?24/7 Wall Street • 12/23/25
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's RybelsusBenzinga • 12/23/25
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?Zacks Investment Research • 12/23/25